May 7, 2021 -- Evotec announced on May 6 a new program that aims to accelerate translational research from the U.K.'s academic life science ecosystem in collaboration with Bristol-Myers Squibb (BMS).
The company launched beLab1407, a new $20 million program to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the U.K.'s top-tier academic institutions.
The program aims to advance innovation in therapeutics from academia to patient benefit, as well as creating spinout companies in the process.